Ghulam J Mufti

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi request reprint Pathobiology, classification, and diagnosis of myelodysplastic syndrome
    Ghulam J Mufti
    Department of Haematological Medicine, Leukemia Science Laboratories, Guy King s and St Thomas School of Medicine, King s College Hospital, Denmark Hill, SE5 9RS London, UK
    Best Pract Res Clin Haematol 17:543-57. 2004
  2. ncbi request reprint Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia
    Barbara Ann Guinn
    Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, King s College London, London SE5 9NU, UK
    Biochem Biophys Res Commun 333:703-13. 2005
  3. doi request reprint CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
    Piers E M Patten
    Department of Haematological and Molecular Medicine, King s College London, Rayne Institute, London, USA
    Blood 111:5173-81. 2008
  4. doi request reprint Myelodysplastic syndromes: who and when in the course of disease to transplant
    Ghulam J Mufti
    Department of Haematological Medicine, King s College London, London, United Kingdom
    Hematology Am Soc Hematol Educ Program 2012:49-55. 2012
  5. ncbi request reprint Changing the treatment paradigm in myelodysplastic syndromes
    Ghulam J Mufti
    Kings College London and Kings College Hospital, Department of Haematological Medicine, London SE5 9RS UK
    Cancer Control 15:14-28. 2008
  6. doi request reprint Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
    Ghulam J Mufti
    Department of Haematology, King s College Hospital, Denmark Hill, London, SE5 9RS United Kingdom
    Haematologica 93:1712-7. 2008
  7. ncbi request reprint Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes
    Zi Yi Lim
    Department of Haematological Medicine, Kings College London and Kings College Hospital, UK
    Br J Haematol 135:201-9. 2006
  8. ncbi request reprint Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes
    Zi Yi Lim
    Department of Haematological Medicine, Kings College London and Kings College Hospital, Denmark Hill, London, UK
    Br J Haematol 138:517-26. 2007
  9. doi request reprint Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab
    Katie Matthews
    The Anthony Nolan Research Institute, Royal Free Hospital, London, UK
    Br J Haematol 149:879-89. 2010
  10. doi request reprint Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
    Alexander E Smith
    Department of Hematologic Medicine, King s College London School of Medicine, London, United Kingdom
    Blood 116:3923-32. 2010

Detail Information

Publications95

  1. ncbi request reprint Pathobiology, classification, and diagnosis of myelodysplastic syndrome
    Ghulam J Mufti
    Department of Haematological Medicine, Leukemia Science Laboratories, Guy King s and St Thomas School of Medicine, King s College Hospital, Denmark Hill, SE5 9RS London, UK
    Best Pract Res Clin Haematol 17:543-57. 2004
    ..As the functional mechanisms behind these chromosomal changes are being revealed, new therapies based on these mechanisms are currently being made and tested...
  2. ncbi request reprint Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia
    Barbara Ann Guinn
    Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, King s College London, London SE5 9NU, UK
    Biochem Biophys Res Commun 333:703-13. 2005
    ..We have identified a number of CT antigens with expression in presentation AML samples but not normal donor samples, which may provide effective targets for future immunotherapy treatments early in disease...
  3. doi request reprint CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
    Piers E M Patten
    Department of Haematological and Molecular Medicine, King s College London, Rayne Institute, London, USA
    Blood 111:5173-81. 2008
    ....
  4. doi request reprint Myelodysplastic syndromes: who and when in the course of disease to transplant
    Ghulam J Mufti
    Department of Haematological Medicine, King s College London, London, United Kingdom
    Hematology Am Soc Hematol Educ Program 2012:49-55. 2012
    ....
  5. ncbi request reprint Changing the treatment paradigm in myelodysplastic syndromes
    Ghulam J Mufti
    Kings College London and Kings College Hospital, Department of Haematological Medicine, London SE5 9RS UK
    Cancer Control 15:14-28. 2008
    ..Timing of available therapies, including stem cell transplantation, should be incorporated into the new treatment paradigm, with end goals of prolonging survival and optimizing patient outcomes...
  6. doi request reprint Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
    Ghulam J Mufti
    Department of Haematology, King s College Hospital, Denmark Hill, London, SE5 9RS United Kingdom
    Haematologica 93:1712-7. 2008
    ..Recommendations should be applied in the context of the WHO classification...
  7. ncbi request reprint Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes
    Zi Yi Lim
    Department of Haematological Medicine, Kings College London and Kings College Hospital, UK
    Br J Haematol 135:201-9. 2006
    ..RIC regimens using VUD was associated with durable long-term survival even in older patients with MDS, and the use of a pre-transplant comorbidity index may help to improve patient selection for transplantation...
  8. ncbi request reprint Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes
    Zi Yi Lim
    Department of Haematological Medicine, Kings College London and Kings College Hospital, Denmark Hill, London, UK
    Br J Haematol 138:517-26. 2007
    ..Future studies need to be directed towards establishing the underlying factors that dictate T-cell engraftment, expansion and homing post-transplantation...
  9. doi request reprint Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab
    Katie Matthews
    The Anthony Nolan Research Institute, Royal Free Hospital, London, UK
    Br J Haematol 149:879-89. 2010
    ....
  10. doi request reprint Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
    Alexander E Smith
    Department of Hematologic Medicine, King s College London School of Medicine, London, United Kingdom
    Blood 116:3923-32. 2010
    ..On multivariate analysis, age (> 50 years) was associated with a higher incidence of TET2 mutation (P = .02)...
  11. doi request reprint IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
    Shahram Y Kordasti
    Department of Haematological Medicine, King s College London, The Rayne Institute, London, UK
    Br J Haematol 145:64-72. 2009
    ..The 'unfavourable' Th17:Tregs ratio in low risk MDS may explain the higher risk of autoimmunity and the improved response to immune suppression in patients with low risk MDS compared to those with high risk disease...
  12. pmc Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
    Terry J Gaymes
    Department of Haematological, Medicine, King s College, London, The Rayne Institute, 123 Coldharbour Lane, London, UK
    Haematologica 94:638-46. 2009
    ....
  13. doi request reprint Anti-tumor immunity in a model of acute myeloid leukemia
    Adam T C Cheuk
    Department of Haematological Medicine, Allergy and Respiratory Science, MRC Asthma UK Centre in Allergic Mechanisms of Asthma, King s College London School of Medicine, London, UK
    Leuk Lymphoma 50:447-54. 2009
    ..In human allogeneic mixed lymphocyte reactions (MLRs), we found no single costimulatory molecule was more effective, suggesting that the induction of a universal anti-tumor response will require a combination of costimulatory molecules...
  14. doi request reprint Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes
    Pramila Krishnamurthy
    Department of Haematological Medicine, King s College Hospital, London, UK
    Biol Blood Marrow Transplant 19:562-8. 2013
    ..We demonstrate that pDLI safely promotes durable remission after TCD RIC HSCT for AML or MDS, and that tDLI salvages patients after late relapse with greater efficacy...
  15. pmc Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab
    Katie Matthews
    Anthony Nolan Research Institute, Royal Free Hospital, London, UK
    Haematologica 94:956-66. 2009
    ....
  16. ncbi request reprint Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures
    Wendy Ingram
    Department of Haematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, SE5 9NU, UK
    Cancer Immunol Immunother 58:1679-90. 2009
    ..Vaccination with LV-CD80/IL2 therefore provides a potential strategy to enhance anti-leukaemia immune responses without a concomitant stimulation of Treg-mediated inhibition of cytotoxic immunological responses...
  17. ncbi request reprint Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study
    Wendy Ingram
    Department of Haematological Medicine, King s College London, London, UK
    Br J Haematol 145:749-60. 2009
    ..4% to 22.5%). These studies demonstrated that vaccination of patients with CD80/IL2-transduced AML cells could provide a powerful strategy for T/NK cell-mediated stimulation of anti-leukaemic immunological responses...
  18. ncbi request reprint TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
    Austin G Kulasekararaj
    Department of Haematological Medicine, King s College London, School of Medicine, London, UK
    Br J Haematol 160:660-72. 2013
    ..The relatively common occurrence of these mutations in two different prognostic spectrums of MDS, i.e. isolated 5q- and CK with -5/5q-, possibly implies two different mechanistic roles for TP53 protein...
  19. doi request reprint Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma
    Wendy Ingram
    Department of Haematological Medicine, King s College London and Kings College Hospital, London, UK
    Br J Haematol 141:235-43. 2008
    ..Furthermore, the ability to re-induce remissions with donor leucocytes provides additional benefit in favour of allogeneic HSCT...
  20. doi request reprint Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome
    Azim M Mohamedali
    Department of Haematological Medicine, King s College London, Rayne Institute, London, United Kingdom
    Blood 122:567-70. 2013
    ..Our results show the potential utility of PB as a surrogate for BM for MDS patients, thus avoiding the need for repeated BM aspirates particularly in elderly patients and those with fibrotic or hypocellular marrows. ..
  21. doi request reprint Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription
    Andrea G S Buggins
    Department of Haematological Medicine, King s College London, London, United Kingdom
    Cancer Res 70:7523-33. 2010
    ..This type of interaction in the peripheral vasculature may explain the constitutive NF-κB activation and the overexpression of Bcl-2 family proteins commonly seen in this disease...
  22. pmc A functional assay for microRNA target identification and validation
    Joop Gaken
    Department of Haematological Medicine, King s College London, Rayne Institute, London SE5 9NU, UK
    Nucleic Acids Res 40:e75. 2012
    ..Identification of MAFB and five additional targets and their subsequent confirmation as mir-130a targets by western blot analysis and knockdown experiments validates this strategy for the functional identification of miRNA targets...
  23. doi request reprint Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimens
    Aleksandar Mijovic
    Department of Haematological Medicine, King s College Hospital, London, UK
    Br J Haematol 142:444-52. 2008
    ..However, transfusion requirements were significantly higher in the SCo group, due at least partly to earlier onset of bone marrow hypoplasia...
  24. doi request reprint Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL)
    M Mansour Ceesay
    Department of Haematological Medicine, King s College Hospital NHS Foundation Trust and King s College London, London, UK
    Leuk Res 36:857-61. 2012
    ..In conclusion CHOP-Z is safe and in those who achieve a complete response it was associated with prolonged overall survival...
  25. doi request reprint Haematopoietic stem cell transplantation for acquired aplastic anaemia
    Moya E Young
    aHaematology Department, Kings College Hospital bKings College London, London, UK
    Curr Opin Hematol 20:515-20. 2013
    ..Here we review recently published data that highlight the improvements and current issues...
  26. pmc The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
    Benedetta Costantini
    King s College London, Department of Haematological Medicine, London, UK
    Haematologica 98:1196-205. 2013
    ..These findings are important in correlating the clinically relevant immunomodulatory effects of 5-azacytidine. ..
  27. doi request reprint Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome
    Azim M Mohamedali
    Department of Haematological Medicine, King s College London School of Medicine, London, UK
    J Clin Oncol 27:4002-6. 2009
    ..We investigated the sequence integrity of 4q24 candidate tumor suppressor gene TET2 in MDS patients with UPD on chromosome 4...
  28. ncbi request reprint Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation
    ZiYi Lim
    Department of Haematological Medicine, Kings College London and Kings College Hospital, Denmark Hill SE5 9RS, UK
    J Infect 54:e83-6. 2007
    ..9% and 3.0% respectively. Despite in vivo T-cell depletion with alemtuzumab, the incidence of toxoplasma disease in our cohort was comparable with previously reported T-cell replete HSCT studies...
  29. doi request reprint Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia
    Judith C Marsh
    Department of Hematological Medicine, King s College Hospital King s College London, London, UK
    Blood 118:2351-7. 2011
    ..001) and age (92% for age < 50 years vs 71% ≥ 50 years, P < .001). Our data suggest that the use of an alemtuzumab-based HSCT regimen for SAA results in durable engraftment with a low incidence of chronic GVHD...
  30. doi request reprint Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation
    Rachel H Westbrook
    Institute of Liver Studies, King s College Hospital, National Health Service Foundation Trust, London, United Kingdom
    Liver Transpl 18:819-27. 2012
    ..005). In conclusion, the presence of JAK2V617F predicts hepatic and extrahepatic thrombotic complications after LT. Testing for TET2 mutations can identify another 7% of idiopathic BCS patients with molecular MPDs...
  31. ncbi request reprint Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning
    Aloysius Y L Ho
    Department of Haematological Medicine, King s College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    Blood 104:1616-23. 2004
    ..RIC allogeneic HSCT using this protocol appears to be safe and permits durable donor engraftment. Longer follow-up is required to confirm any potential survival advantage...
  32. pmc Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome
    Syed A Mian
    King s College London School of Medicine, Department of Haematological Medicine, London, UK
    Haematologica 98:1058-66. 2013
    ....
  33. ncbi request reprint Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome
    Victoria T Potter
    Department of Haematological Medicine, King s College Hospital, London, UK
    Biol Blood Marrow Transplant 20:111-7. 2014
    ..Overall, these data demonstrate good 5-yr OS for patients with MDS and MDS-AML undergoing alemtuzumab-based RIC-HSCT. The low rate of chronic GVHD is encouraging, and comparative studies with other RIC protocols are warranted...
  34. doi request reprint Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
    Austin G Kulasekararaj
    Department of Haematological Medicine, King s College London School of Medicine, London, UK
    Br J Haematol 162:587-605. 2013
    ..The deluge of this molecular information, once validated on a larger cohort, will be incorporated into prognostic systems and clinical practise, and also hopefully aid in MDS therapeutics, especially in guiding targeted therapy. ..
  35. ncbi request reprint Development of a whole cell vaccine for acute myeloid leukaemia
    Adam T C Cheuk
    Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, The Rayne Institute, King s College London, 123 Coldharbour Lane, London, SE5 9NU, UK
    Cancer Immunol Immunother 55:68-75. 2006
    ..We will aim to provide a brief overview of the latest data from our group and considerations for the use of this treatment modality in clinical trials for AML...
  36. pmc Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies
    Terry J Gaymes
    Department of Haematological Medicine, King s College London, Leukaemia Sciences Laboratories, The Rayne Institute, Denmark Hill Campus, London UK
    Haematologica 98:1397-406. 2013
    ..Microsatellite instability is significantly correlated with chromosomal instability in myeloid malignancies. ..
  37. pmc Epigenetics of human T cells during the G0-->G1 transition
    Alexander E Smith
    King s College London, Department of Haematological Medicine, Leukaemia Sciences Laboratories, Rayne Institute, London, United Kingdom
    Genome Res 19:1325-37. 2009
    ..Furthermore, a drop in meC also marks 3' transcription termination, and a peak of meC occurs at stop codons. This mimics the 3' nucleosomal distribution in yeast, which we show does not occur in human T cells...
  38. ncbi request reprint High efficiency protein transduction of quiescent and proliferating primary hematopoietic cells
    Nicholas C Lea
    Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, Rayne Institute, 123 Coldharbour Lane, London, SE5 9NU, UK
    J Biochem Biophys Methods 55:251-8. 2003
    ..This method will allow us to study of the effects of a variety of gene products in cell types that were previously resistant to gene transfection studies...
  39. ncbi request reprint An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia
    Lucas Chan
    King s College London, Department of Haematological Molecular Medicine, The Rayne Institute, 123 Coldharbour Lane, SE5 9NU, London, UK
    Cancer Immunol Immunother 55:1017-24. 2006
    ....
  40. ncbi request reprint Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data
    ZiYi Lim
    Haematological Medicine, Kings College London and Kings College Hospital, London, UK
    Br J Haematol 136:448-50. 2007
    ..10%, P = 0.19). None of the nine myeloablative HSCT recipients survived (median survival: 9 d). Six of the 15 reduced-intensity conditioned HSCT recipients survived beyond 1 year (median survival: 1050 d, range: 438-1437)...
  41. ncbi request reprint Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
    Azim Mohamedali
    Department of Haematological Medicine, King s College Hospital, King s College London School of Medicine, Denmark Hill, London, United Kingdom
    Blood 110:3365-73. 2007
    ..001). We show, for the first time, that SNP microarray analysis in low-risk MDS patients reveals hitherto unrecognized UPD and CN changes that may allow stratification of these patients for early therapeutic interventions...
  42. doi request reprint Functional characterization of CD4+ T cells in aplastic anemia
    Shahram Kordasti
    Department of Haematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, United Kingdom
    Blood 119:2033-43. 2012
    ..The clonally restricted expansion of Th1 cells is most likely to be antigen-driven, and induces an inflammatory environment, that exacerbate the functional impairment of Tregs, which are reduced in number...
  43. ncbi request reprint Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy
    Daniel Creamer
    Department of Dermatology, King s College Hospital, Denmark Hill, London SE5 9RS, England
    Arch Dermatol 143:1157-62. 2007
    ..Within a large population of individuals who underwent allogeneic stem cell transplantation because of hematologic malignancy, a group of patients was identified in whom severe and persistent eczema developed...
  44. doi request reprint Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells
    Karthik Ramasamy
    Division of Cancer Studies, Department of Haematological Medicine, Kings College London, UK
    Br J Haematol 157:564-79. 2012
    ..This new experimental platform provides a more precise screening of new therapeutics for improved efficacy of tumour cell killing within the bone marrow microenvironment...
  45. pmc Proteomic and protein interaction network analysis of human T lymphocytes during cell-cycle entry
    Stephen J Orr
    Department of Haematological Medicine, Leukaemia Sciences Laboratories, Rayne Institute, King s College London, UK
    Mol Syst Biol 8:573. 2012
    ....
  46. ncbi request reprint Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma
    Victor Noriega
    Department of Haematological Medicine, King s College London and Kings College Hospital, London, UK Electronic address
    Leuk Res 38:737-43. 2014
    ..Incidence of acute and chronic GVHD was 16.6% and 22%. 29% of BEAM-Allo patients received DLI (all but two remain in CR and alive). Our data supports Allo-HSCT as a potential curative treatment for selected patients with FL. ..
  47. doi request reprint The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients
    Sydney Shall
    Department of Haematological Medicine, The Rayne Institute, Kings College London, Denmark Hill Campus, London, UK
    Methods Mol Biol 780:239-66. 2011
    ....
  48. ncbi request reprint Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome
    Raj K Patel
    Department of Haematological Medicine, King s College Hospital, London, England
    Gastroenterology 130:2031-8. 2006
    ..A clonal mutation in JAK2 tyrosine kinase (JAK2V617F) occurs in a high proportion of patients with MPD and is of use in the characterization of latent MPD in BCS...
  49. ncbi request reprint Antiapoptotic microenvironment of acute myeloid leukemia
    Dragana Milojkovic
    Department of Haematological Medicine, Leukaemia Sciences, Guy s, King s and St Thomas School of Medicine, Rayne Institute, London, United Kingdom
    J Immunol 173:6745-52. 2004
    ..Reversal of these immunosuppressive effects and restoration of normal immune responses in patients with AML would improve the success of immunotherapy protocols...
  50. ncbi request reprint Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: report of three cases and review of literature
    Karthik Ramasamy
    Department of Haematological Medicine, King s College London and King s College Hospital, UK
    Leuk Lymphoma 48:290-4. 2007
    ..Early and accurate diagnosis is essential and patients should be managed along the lines of high risk AML...
  51. ncbi request reprint Allogeneic transplantation for myelodysplastic syndrome (MDS)
    Wendy Ingram
    Department of Haematological Medicine, Kings College Hospital and Kings College London, Denmark Hill, London, SE5 9RS, UK
    Blood Rev 21:61-71. 2007
    ..The graft versus dysplasia effect resulting from allogeneic HSCT and the infusion of donor leukocytes has led to a greater understanding of the immunological mechanisms that govern outcome following transplantation in MDS...
  52. ncbi request reprint Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors
    Terry J Gaymes
    Department of Haematological Medicine, Leukaemia Sciences Laboratories, The Rayne Institute, Kings College London, Denmark Hill Campus, London, UK
    Haematologica 93:1886-9. 2008
    ....
  53. doi request reprint Van-den Berghe's 5q- syndrome in 2008
    Azim Mohamedali
    Department of Haematological Medicine, Kings College London, London, UK
    Br J Haematol 144:157-68. 2009
    ..This review examines the potential role of several genes, including RPS14, in the pathogenesis of the 5q- syndrome and recent advances in clinical management, with particular emphasis on the role and mechanism of action of lenalidomide...
  54. doi request reprint Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia
    ZiYi Lim
    Department of Haematological Medicine, Kings College London and Kings College Hospital, Denmark Hill, London, United Kingdom
    J Clin Oncol 28:405-11. 2010
    ....
  55. ncbi request reprint Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone
    Karthik Ramasamy
    Department of Haematological Medicine, Kings College London and Kings College Hospital, Denmark Hill, London, United Kingdom SE5 9RS
    Haematologica 91:ECR44. 2006
    ..Thalidomide may be an effective therapeutic agent against AITL, and given the poor prognosis of AITL, prospective clinical studies with either thalidomide or one of the thalidomide analogues are warranted...
  56. ncbi request reprint Optimised SEREX technique for the identification of leukaemia-associated antigens
    Barbara Ann Guinn
    Leukaemia Science Laboratories, Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, Denmark Hill Campus, Rayne Institute, 123 Coldharbour Lane, London, UK
    J Immunol Methods 264:207-14. 2002
    ..Using the methodology described, we have shown SEREX to be effective for the isolation of leukaemia-associated antigens, which may act as targets for immunotherapy...
  57. ncbi request reprint Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins
    Nicola Brady
    Department of Haematological Medicine, Leukaemia Sciences Laboratories, The Rayne Institute, Guy s, King s, St Thomas School of Medicine, Denmark Hill, London SE5 9NU, United Kingdom
    Cancer Res 63:1798-805. 2003
    ..These data suggest that the generation of increased constitutive DNA damage may be a common pathway for the creation of NHEJ-dependent genomic instability...
  58. ncbi request reprint Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cells
    Feyruz V Rassool
    Department of Haematological Medicine, The Rayne Institute, Guy s, King s and Thomas School of Medicine, 123 Coldharbour Lane, London SE5 9NU, UK
    Oncogene 22:8749-57. 2003
    ..Thus, our data indicate that constitutive DNA damage is coupled to delayed DNA replication in BS cells...
  59. ncbi request reprint Cyclin D2 controls B cell progenitor numbers
    Azim Mohamedali
    Leukaemia Sciences, Guy s, King s, St Thomas School of Medicine, Rayne Institute, 123 Coldharbour Lane, London SE5 9RS, UK
    J Leukoc Biol 74:1139-43. 2003
    ..We conclude that cyclin D2 is rate-limiting for the production of B lymphoid progenitor cells whose proliferation does not depend on BCR signaling...
  60. ncbi request reprint Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning
    Kavita Raj
    Guy s and St Thomas NHS Hospitals Foundation Trusts, London, United Kingdom Department of Haematological Medicine, King s College Hospital, London, United Kingdom
    Biol Blood Marrow Transplant 20:890-5. 2014
    ..Our results suggest that PBSC can be substituted safely and effectively for bone marrow as the graft source for haploidentical transplantation after RIC...
  61. ncbi request reprint AKT1 (E17K) mutation in pancreatic cancer
    Azim Mohamedali
    Department of Haematological Medicine, Kings College London, 123 Coldharbour Lane, London
    Technol Cancer Res Treat 7:407-8. 2008
    ..This mutation was un-detectable in pancreatic cancer tissue samples (n=65) and pancreatic cell line (n=10) DNA suggesting that pancreatic cancer progression is mainly dependent on the K-Ras mutation...
  62. ncbi request reprint Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party
    Judith C Marsh
    Department of Haematological Medicine, King s College Hospital King s College London, London, United Kingdom
    Blood 119:5391-6. 2012
    ..9, P = .003) and age more than 37 years (hazard ratio = 4.7, P = .0008) were independent adverse risk factors for survival. This study was registered at www.clinicaltrials.gov as NCT00471848...
  63. ncbi request reprint Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer
    Terry J Gaymes
    Department of Haematological Medicine, Leukaemic Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill, London SE5 9NU, UK
    Cancer Res 62:2791-7. 2002
    ..Our findings suggest that an overactive NHEJ system and, specifically, aberrant Ku70/86 activity is a candidate mechanism for chromosomal instability in myeloid leukemias...
  64. doi request reprint Bilateral retinal vasculopathy associated with autosomal dominant dyskeratosis congenita
    Sara Vaz-Pereira
    Medical Retina Department, Moorfields Eye Hospital NHS Foundation Trust, London, UK
    Eur J Ophthalmol 23:772-5. 2013
    ..To report a case of autosomal dominant dyskeratosis congenita (AD-DC) complicated by bilateral retinal vasculopathy and proliferative retinopathy with vitreous hemorrhage in the right eye, in the absence of pancytopenia.
..
  65. ncbi request reprint Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?
    Terry J Gaymes
    Department of Haematological Medicine, Leukemia Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill Campus, London, United Kingdom
    Mol Cancer Res 4:563-73. 2006
    ..Our data indicate that induction of apoptosis by HDI may result predominantly through accumulation of excessive DNA damage in leukemia cells, leading to activation of apoptosis...
  66. ncbi request reprint CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
    Shahram Y Kordasti
    Department of Hematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, UK
    Blood 110:847-50. 2007
    ..032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease...
  67. ncbi request reprint Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia
    Barbara Ann Guinn
    Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, King s College London, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK
    Biochem Biophys Res Commun 335:1293-304. 2005
    ..Antigen presentation assays using monocyte-derived dendritic cells (mo-DCs) showed that PASD1 could stimulate autologous T-cell responses, suggesting that PASD1 could be a promising target for future immunotherapy clinical trials...
  68. pmc Commitment point during G0-->G1 that controls entry into the cell cycle
    Nicholas C Lea
    Department of Haematological Medicine, Leukaemia Sciences Laboratories, Guy s, King s and St Thomas School of Medicine, London SE5 9NU, United Kingdom
    Mol Cell Biol 23:2351-61. 2003
    ....
  69. doi request reprint The non-transplant treatment of myelodysplastic syndromes-what's on the horizon?
    Austin G Kulasekararaj
    Department of Haematological Medicine, King s College London School of Medicine, London, UK
    Semin Hematol 49:350-60. 2012
    ....
  70. ncbi request reprint Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens
    Jane E Parker
    Department of Haematological Medicine, Guy s, King s, Thomas School of Medicine, London, UK
    Br J Haematol 119:144-54. 2002
    ..5 year DFS to those receiving conventional regimens...
  71. ncbi request reprint T-cell lymphoblastic lymphoma presenting as an intra-muscular mass
    ZiYi Lim
    Department of Haematological Medicine, Kings College London and Kings College Hospital, UK
    Br J Haematol 132:537. 2006
  72. ncbi request reprint Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab
    Matthew R Foxton
    Institute of Liver Studies, King s College Hospital, London SE5 9RS, UK
    Liver Transpl 11:839-42. 2005
    ..Rituximab may be useful in preventing progression of NHL until surgical extirpation is possible...
  73. ncbi request reprint Role of 4-1BB:4-1BB ligand in cancer immunotherapy
    Adam T C Cheuk
    Leukaemia Science Laboratories, Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK
    Cancer Gene Ther 11:215-26. 2004
    ..In particular, we will describe the structure and function of the 4-1BB molecule, its receptor and how 4-1BB:4-1BBL costimulation has and may be used for the immunotherapy of cancer...
  74. ncbi request reprint Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab
    Andrea G S Buggins
    Department of Haematological Medicine, Guy s, King s and Thomas School of Medicine, Denmark Hill, London, England
    Blood 100:1715-20. 2002
    ....
  75. ncbi request reprint Increased error-prone non homologous DNA end-joining--a proposed mechanism of chromosomal instability in Bloom's syndrome
    Terry J Gaymes
    Department of Haematological Medicine, Leukaemic Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill, London SE5 9NU, UK
    Oncogene 21:2525-33. 2002
    ..This aberrant repair is dependent upon the presence of the Ku70/86 heterodimer, a key component in the NHEJ pathway. We propose that aberrant NHEJ is a candidate mechanism for the generation of chromosomal instability in BS...
  76. ncbi request reprint The myelodysplastic syndromes: a matter of life or death
    Jane E Parker
    Department of Haematological Medicine, Norfolk and Norwich University Hospital, Norwich, UK
    Acta Haematol 111:78-99. 2004
    ..This paper outlines the apoptotic process in normal hematopoietic cells and summarizes current data regarding the role, potential causes and clinical implications of altered apoptosis in MDS...
  77. ncbi request reprint Targeted therapies in myeloid leukemia
    Alison M John
    Leukaemia Sciences Laboratories, Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, King s College London, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK
    Semin Cancer Biol 14:41-62. 2004
    ....
  78. ncbi request reprint Apoptosis in the myelodysplastic syndromes
    Nigel B Westwood
    Department of Haematology, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Curr Hematol Rep 2:186-92. 2003
    ..Expression profiling and proteomic technologies may offer the best means to unravel this process...
  79. ncbi request reprint The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia
    Barbara Ann Guinn
    Br J Haematol 134:238-9. 2006
  80. ncbi request reprint Analysis of CHK2 in patients with myelodysplastic syndromes
    Dilek Aktas
    Department of Genetics, Hacettepe University Children s Hospital, 06100 Sýhhýye, Ankara, Turkey
    Leuk Res 26:985-7. 2002
    ..We conclude that alterations of CHK2 and possible involvement in the pathogenesis of MDS may be a rare event...
  81. ncbi request reprint BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia
    Nader Omidvar
    Institut National de la Sante et de la Recherche Medicale U718 and 728, Universite Paris 7 Denis Diderot, Faculte de Medicine, Institut Universitaire d Hématologie IFR105, Paris, France
    Cancer Res 67:11657-67. 2007
    ..The colocalization of BCL-2 and RAS in the bone marrow of MDS/AML patients offers targeting either oncogene as a therapeutic strategy...
  82. ncbi request reprint Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells
    Abdelkader Essafi
    Cancer Research UK Labs, Department of Cancer Medicine, MRC Cyclotron Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Oncogene 24:2317-29. 2005
    ..Thus, STI571 induces an accumulation of FoxO3a activity which in turn binds directly to an FHRE in the promoter to activate Bim expression and apoptosis...
  83. ncbi request reprint Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?
    Feyruz V Rassool
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201 1509, USA
    Cancer Res 67:8762-71. 2007
    ..These data suggest treatment strategies that target RAS/RAC pathways and ROS production in human MDS/AML...
  84. ncbi request reprint P15INK4B is not mutated in adult familial myelodysplastic syndromes
    Elizabeth Cameron
    Br J Haematol 119:277-9. 2002
  85. ncbi request reprint Emerging therapeutic and supportive care approaches for the myelodisplastic syndromes
    Ghulam J Mufti
    Rev Clin Exp Hematol 8:E4. 2004
  86. pmc Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
    Aristoteles Giagounidis
    St Johannes Hospital, Medizinische Klinik II, An der Abtei 7 11, 47166 Duisburg, Germany
    Ann Hematol 87:345-52. 2008
    ....
  87. ncbi request reprint The leukaemia-associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cells
    Frances A K Denniss
    Br J Haematol 138:668-9. 2007
  88. ncbi request reprint A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
    Pierre Fenaux
    Hopital Avicenne, Paris, France
    Blood 109:4158-63. 2007
    ..In this study, durable responses and acceptable side effects were observed. Tipifarnib is an active agent for the treatment of patients with intermediate- to high-risk MDS...
  89. pmc Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the Euro
    Rodrigo Martino
    Hematology Department of Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Blood 108:2928-36. 2006
    ..001]). These findings may help in the interpretation and design of future studies on secondary prophylaxis of IA after an allo-HSCT...
  90. ncbi request reprint Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
    Rodrigo Martino
    Division of Clinical Hematology, Hopital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Spain
    Blood 108:836-46. 2006
    ....
  91. ncbi request reprint Mobilization of hematopoietic progenitors in low-grade myelodysplastic syndromes
    Aleksandar Mijovic
    Haematologica 91:572-3. 2006
    ..Only three out of 15 patients had adequate progenitor cell collections for potential use in autologous transplantation...
  92. ncbi request reprint Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
    Lewis R Silverman
    Myelodisplastic Syndrome Myeloproliferative Disease Center, Mount Sinai School of Medicine, NewYork, NY, USA
    Nat Clin Pract Oncol 2:S12-23. 2005
    ..g. according to age, risk, classification, and cytogenetic profile), and the combination strategies, particularly with histone deacetylase inhibitors, in the management of MDS...
  93. ncbi request reprint Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction
    Stephen B Baylin
    Cancer Biology Division at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Nat Clin Pract Oncol 2:S1-3. 2005
  94. ncbi request reprint High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders
    Stella J Bowcock
    Br J Haematol 134:242-3. 2006